Research Analysts Issue Forecasts for AURA Q1 Earnings

Aura Biosciences, Inc. (NASDAQ:AURA) – Leerink Partnrs issued their Q1 2025 EPS estimates for Aura Biosciences in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($0.49) per share for the quarter. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. Leerink Partnrs also issued estimates for Aura Biosciences’ Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.47) EPS and Q4 2025 earnings at ($0.51) EPS.

Other equities research analysts also recently issued reports about the company. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a research report on Thursday, November 14th. BTIG Research increased their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Finally, Scotiabank increased their target price on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Friday, October 18th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Stock Performance

Shares of AURA opened at $7.80 on Friday. The business’s 50-day moving average is $8.20 and its two-hundred day moving average is $8.87. The company has a market capitalization of $389.61 million, a P/E ratio of -4.51 and a beta of 0.29. Aura Biosciences has a fifty-two week low of $6.63 and a fifty-two week high of $12.38.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.02.

Institutional Trading of Aura Biosciences

Several institutional investors and hedge funds have recently modified their holdings of AURA. China Universal Asset Management Co. Ltd. purchased a new position in shares of Aura Biosciences during the fourth quarter valued at approximately $87,000. AlphaQuest LLC purchased a new position in shares of Aura Biosciences during the fourth quarter valued at approximately $136,000. SG Americas Securities LLC purchased a new position in shares of Aura Biosciences during the third quarter valued at approximately $169,000. JPMorgan Chase & Co. lifted its stake in shares of Aura Biosciences by 107.5% during the third quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company’s stock valued at $477,000 after buying an additional 27,718 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Aura Biosciences by 14.6% during the second quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock valued at $487,000 after buying an additional 8,194 shares during the period. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Insider Transactions at Aura Biosciences

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the sale, the insider now directly owns 304,692 shares of the company’s stock, valued at $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Janet Jill Hopkins sold 11,822 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.36, for a total transaction of $110,653.92. Following the completion of the sale, the insider now directly owns 151,693 shares of the company’s stock, valued at approximately $1,419,846.48. This trade represents a 7.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 28,778 shares of company stock valued at $240,706. Insiders own 5.40% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.